News
Covaxin Phase 3 Trial Update: Bharat Biotech's COVID-19 Vaccine Data Shows 77% Efficacy, Says Lancent
The Lancet, a prestigious medical journal has said that Covaxin's phase 3 data demonstrates 77.8% efficacy against the COVID-19.
After a week of WHO granting the emergency Use Listing (EUL) to Bharat Biotech's Covaxin, The Lancet, a prestigious medical journal has said that Covaxin's phase 3 data demonstrates 77.8% efficacy against the COVID-19.
Check the tweet here:
The Lancet peer-review confirms the efficacy analysis of Bharat Biotech's Covaxin - As per phase-three clinical trials data, Covaxin demonstrates 77.8% efficacy against symptomatic COVID19 pic.twitter.com/6tnUneq3e6
— ANI (@ANI) November 12, 2021
(The above story first appeared on LatestLY on Nov 12, 2021 08:02 AM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).
